Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.3
USERS' SCORE
Moderately Good
Based on 57 Reviews
7.7
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
**
Polyunsaturated Fat
0.5 g
**
Monounsaturated Fat
0 g
**
Cholesterol
10 mg
3%
Omega-3 Fish Oil
1000 mg
**
EPA (Eicosapentaenoic Acid)
180 mg
**
DHA (Docosahexaenoic Acid)
120 mg
**
Top Medical Research Studies
9
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
8
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
Read More
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
Most Useful Reviews
9
Cardiovascular benefits
33 people found this helpful
"Mega" omega!!! This quality fish oil contains essential omega-3 fatty acids, which significantly lower cholesterol levels and aid in preventing heart disease. Omega-3 has been noted by oncologists for slowing tumour growth and is effective for various skin ailments. It also reduces allergy symptoms in children, aids in wound healing, and helps with arthritis by promoting anti-inflammatory prostaglandins. Omega-3 is vital for brain function and can help pregnant women develop the embryo. I take it daily to regulate fat metabolism and support overall health.
Read More
8
Strengthens heart health
22 people found this helpful
Omega-3 is crucial for cell membrane strength and brain health. Regular inclusion of these fatty acids can reduce the risk of heart disease, lower blood pressure in hypertensives, and improve mental well-being. It also alleviates joint pain and skin issues. While omega-6 acids can be harmful in excess, omega-3 neutralises their negative effects. I prefer products that state "Omega-3" for higher benefits. This supplement is good value, with a substantial number of capsules, ideal for those who don’t consume enough fish.
Read More
9
Heart health improvement
4 people found this helpful
After starting this omega-3, my heart issues have diminished. I recommend it for anyone experiencing similar challenges. If you found this helpful, please click "YES."
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.3
- All Researches
9
We analyzed the impact of different fatty acid-derived acylcarnitines on heart health. The study found that saturated and monounsaturated acylcarnitines, especially trans-elaidoylcarnitine, significantly impaired heart function and mitochondrial activity, leading to cardiotoxicity.
In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
Read More
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
9
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
9
Omega-3 benefits African Americans’ heart health
We observed that the role of omega-3 fatty acids in heart health showed promising results specifically for African Americans. By comparing matched groups from the VITAL trial, we found that omega-3 supplementation significantly reduced the risk of myocardial infarction in African Americans, while no such benefit was seen in non-Hispanic whites.
This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
Read More
9
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 57 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cardiovascular benefits
33 people found this helpful
"Mega" omega!!! This quality fish oil contains essential omega-3 fatty acids, which significantly lower cholesterol levels and aid in preventing heart disease. Omega-3 has been noted by oncologists for slowing tumour growth and is effective for various skin ailments. It also reduces allergy symptoms in children, aids in wound healing, and helps with arthritis by promoting anti-inflammatory prostaglandins. Omega-3 is vital for brain function and can help pregnant women develop the embryo. I take it daily to regulate fat metabolism and support overall health.
Read More
8
Strengthens heart health
22 people found this helpful
Omega-3 is crucial for cell membrane strength and brain health. Regular inclusion of these fatty acids can reduce the risk of heart disease, lower blood pressure in hypertensives, and improve mental well-being. It also alleviates joint pain and skin issues. While omega-6 acids can be harmful in excess, omega-3 neutralises their negative effects. I prefer products that state "Omega-3" for higher benefits. This supplement is good value, with a substantial number of capsules, ideal for those who don’t consume enough fish.
Read More
9
Heart health improvement
4 people found this helpful
After starting this omega-3, my heart issues have diminished. I recommend it for anyone experiencing similar challenges. If you found this helpful, please click "YES."
Read More
9
Improved heart health
4 people found this helpful
Natrol Omega-3 Fish Oil capsules are fairly large but effective. I've noticed significant benefits: my skin feels smoother, hair sheds less, and I wake up more refreshed. The packaging highlights heart health, and I genuinely hope it supports my cardiovascular system as claimed. Overall, this product is worthy of its positive reputation.
Read More
9
Family health boost
2 people found this helpful
A friend recommended this omega-3, which we all take as a family. It helps in lowering 'bad' cholesterol and supports heart health. The capsules are pleasant and easy to swallow, unlike others we’ve tried. We have all benefitted from this product!
Read More
Frequently Asked Questions
8
Improved vitality
6 people found this helpful
I consistently take omega-3 for its numerous benefits, particularly its effectiveness for overall health. After a few weeks, I've noticed improvements in my energy levels and healthier skin and nails. My heart rate remains steady, and cholesterol levels are normal. This omega-3 supplement doesn't cause any side effects and is easy to swallow. I take two capsules daily for optimal vitality and health.
7.5
Long-term use
4 people found this helpful
I've been taking this omega-3 for around ten months to help maintain my heart disease and brain health. I've felt a positive impact since switching to iHerb for better delivery options. I will continue using it.
9
Heart health improvement
4 people found this helpful
After starting this omega-3, my heart issues have diminished. I recommend it for anyone experiencing similar challenges. If you found this helpful, please click "YES."
9
Family health boost
2 people found this helpful
A friend recommended this omega-3, which we all take as a family. It helps in lowering 'bad' cholesterol and supports heart health. The capsules are pleasant and easy to swallow, unlike others we’ve tried. We have all benefitted from this product!
9
Improved heart health
4 people found this helpful
Natrol Omega-3 Fish Oil capsules are fairly large but effective. I've noticed significant benefits: my skin feels smoother, hair sheds less, and I wake up more refreshed. The packaging highlights heart health, and I genuinely hope it supports my cardiovascular system as claimed. Overall, this product is worthy of its positive reputation.
8
Strengthens heart health
22 people found this helpful
Omega-3 is crucial for cell membrane strength and brain health. Regular inclusion of these fatty acids can reduce the risk of heart disease, lower blood pressure in hypertensives, and improve mental well-being. It also alleviates joint pain and skin issues. While omega-6 acids can be harmful in excess, omega-3 neutralises their negative effects. I prefer products that state "Omega-3" for higher benefits. This supplement is good value, with a substantial number of capsules, ideal for those who don’t consume enough fish.
6
Effective health supplement
6 people found this helpful
This omega-3 product matches the description perfectly. When opened, it smells just like pure fish oil. It aligns with the recommended daily dosage of 1000 mg, and I've felt better since starting it. Remember, proper nutrition and moderation are key alongside any supplement. Ensuring I maintain my omega-3 intake has positively impacted my health, particularly concerning heart disease.
8
Cognitive improvements
8 people found this helpful
As a regular user of supplements, I find omega-3 highly beneficial. It enhances vision and memory, lowers blood pressure, improves joint mobility, and promotes cell regeneration. It also lowers the likelihood of heart disease and combats early ageing. Recommended for anyone, especially seniors. I take it to stabilise my cholesterol and have noticed significant health benefits for myself and my family.
9
Regulates blood lipids
1 people found this helpful
My mother has taken fish oil for years, keeping her blood lipids normal. It effectively controls heart disease and cholesterol levels, making this fish oil both cost-effective and beneficial.
9
Lowers heart health risks
1 people found this helpful
Omega-3 fatty acids are beneficial for lowering blood pressure, triglyceride levels, and the risk of atherosclerosis. They also reduce the likelihood of arrhythmias and heart attacks or strokes, contributing to decreased risk of sudden death from heart disease.
8
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
9
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
8
Omega-3 reduces heart disease risk
We explored the effectiveness of icosapent ethyl, a form of omega-3 fish oil, in lowering heart disease rates among high-risk patients with varying cholesterol levels.
In a clinical trial with statin-treated individuals who had elevated triglycerides, it was found that those taking icosapent ethyl experienced significantly fewer cardiovascular events compared to those on a placebo.
Notably, this benefit was seen regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels, indicating positive outcomes even for patients with well-controlled cholesterol.
In a clinical trial with statin-treated individuals who had elevated triglycerides, it was found that those taking icosapent ethyl experienced significantly fewer cardiovascular events compared to those on a placebo.
Notably, this benefit was seen regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels, indicating positive outcomes even for patients with well-controlled cholesterol.
4
Icosapent ethyl safety evaluation
We explored the real-world safety of icosapent ethyl (IPE), a specific formulation of eicosapentaenoic acid, in comparison to mixed omega-3 polyunsaturated fatty acids (OM-3) in a cohort of US veterans. This evaluation came on the heels of the REDUCE-IT trial, which had suggested that while IPE might offer cardiovascular benefits, it also raised some concerns regarding potential risks for conditions like atrial fibrillation (AF) and major bleeding events.
Using a large dataset from the Veterans Affairs system spanning from 2020 to 2024, we compared the occurrence of new-onset AF and significant bleeding among new users of these treatments. We employed a robust methodology involving pairwise propensity score matching to account for confounding factors, striving to provide a clearer picture of the safety profile of these two therapy options.
Overall, our findings did not show significant differences in safety between IPE and OM-3, with our measures of association remaining consistent with the null hypothesis. However, we could not entirely dismiss the possibility that IPE might be linked to increased risks, hinting at a potential rise in AF rates of up to 63% and a tripling in major bleeding cases.
This highlights an important consideration for both healthcare providers and patients when making decisions around omega-3 treatments for heart health.
Using a large dataset from the Veterans Affairs system spanning from 2020 to 2024, we compared the occurrence of new-onset AF and significant bleeding among new users of these treatments. We employed a robust methodology involving pairwise propensity score matching to account for confounding factors, striving to provide a clearer picture of the safety profile of these two therapy options.
Overall, our findings did not show significant differences in safety between IPE and OM-3, with our measures of association remaining consistent with the null hypothesis. However, we could not entirely dismiss the possibility that IPE might be linked to increased risks, hinting at a potential rise in AF rates of up to 63% and a tripling in major bleeding cases.
This highlights an important consideration for both healthcare providers and patients when making decisions around omega-3 treatments for heart health.
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
5
Eicosapentaenoic acid's uncertain impact
We delved into how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, affects heart disease. Our focus was on recent studies, including two notable trials: REDUCE-IT and STRENGTH. While these trials aimed to evaluate the effectiveness of EPA in reducing major cardiovascular events, they yielded conflicting results, prompting questions about EPA's real impact on cardiovascular health.
The REDUCE-IT trial used highly purified EPA, which showed promise in reducing heart problems, while the STRENGTH trial, which combined EPA with DHA, reported different outcomes. This discrepancy leads us to consider factors like genetic variations and dietary influences that might affect these results.
Moreover, we observed that EPA might influence the fluidity of erythrocyte membranes, a factor that could play a role in cardiovascular health. Interestingly, erythrocyte membrane fluidity might even serve as a new biomarker for assessing cardiovascular risk.
Despite the potential benefits observed in some studies, the overall effectiveness of eicosapentaenoic acid in preventing significant cardiovascular events remains uncertain. As we continue to explore these findings, it’s essential to approach this area of research with caution, especially considering the complexity of cardiovascular health and the various factors at play.
The REDUCE-IT trial used highly purified EPA, which showed promise in reducing heart problems, while the STRENGTH trial, which combined EPA with DHA, reported different outcomes. This discrepancy leads us to consider factors like genetic variations and dietary influences that might affect these results.
Moreover, we observed that EPA might influence the fluidity of erythrocyte membranes, a factor that could play a role in cardiovascular health. Interestingly, erythrocyte membrane fluidity might even serve as a new biomarker for assessing cardiovascular risk.
Despite the potential benefits observed in some studies, the overall effectiveness of eicosapentaenoic acid in preventing significant cardiovascular events remains uncertain. As we continue to explore these findings, it’s essential to approach this area of research with caution, especially considering the complexity of cardiovascular health and the various factors at play.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
- Xu J, Peng T, Kong L, Wei N. A global analysis of the burden of ischemic heart disease attributable to diet low in ω-3 fatty acids between 1990 and 2021. BMC Cardiovasc Disord. 2025;25:188. doi:10.1186/s12872-025-04620-z
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Ryuno Y, Kobayashi JI, Fujimoto Y, Dotare T, Matsue Y, et al. Effect of an Enteral Formula Enriched With ω-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model. J Cardiovasc Pharmacol. 2024;84:590. doi:10.1097/FJC.0000000000001637
- Sun S, Hara A, Johnstone L, Hallmark B, Watkins JC, et al. Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation. Nutrients. 2024;16. doi:10.3390/nu16172933
- Ahmadi M, Askari VR, Shahri B, Mousavi Noghab SM, Jarahi L, et al. Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:881. doi:10.1007/s00210-024-03330-1
- Chen HC, Tai CJ, Huang JY, Kuo TA, Huang YD, et al. Associations of fish oil with cardiovascular disease events: results from the Taiwan longitudinal study in aging. BMC Public Health. 2024;24:1979. doi:10.1186/s12889-024-19512-8
- Yu Y, Gao M, Xu H. Ginger Extract and Omega-3 Fatty Acids Supplementation: A Promising Strategy to Improve Diabetic Cardiomyopathy. Physiol Res. 2024;73:351.
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, et al. Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor. Nutrients. 2024;16. doi:10.3390/nu16244318
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Amangurbanova M, Daher R, Asbeutah AA, Vemuri B, Mirza H, et al. Higher epicardial adipose tissue volume is associated with higher coronary fatty plaque volume and is regulated by waist circumference but not EPA+DHA supplementation. J Clin Lipidol. 2024;18:e773. doi:10.1016/j.jacl.2024.06.006
- Kumakura H, Funada R, Matsuo Y, Iwasaki T, Nakashima K, et al. Eicosapentaenoic Acid Level Predicts Long-Term Survival and Cardiovascular or Limb Event in Peripheral Arterial Disease. Ann Vasc Dis. 2024;17:135. doi:10.3400/avd.oa.23-00079
- Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, et al. Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies. Nutrients. 2024;16. doi:10.3390/nu16111610
- Asbeutah AA, Daher R, Malik A, Hariri E, Alfaddagh A, et al. The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial. Am J Cardiol. 2024;225:98. doi:10.1016/j.amjcard.2024.06.001
- Sudo Y, Morimoto T, Tsushima R, Oka A, Sogo M, et al. Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. J Am Heart Assoc. 2024;13:e033969. doi:10.1161/JAHA.123.033969
- Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. doi:10.1161/CIRCULATIONAHA.123.065520
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
- Lv L, Guo Y, Zheng Z, Li B. Blood metabolites mediate effects of breakfast skipping on heart failure via Mendelian randomization analysis. Sci Rep. 2024;14:18957. doi:10.1038/s41598-024-69874-7
- Wang Y, Yang B, Wang C. The association between fatty acids and atherosclerotic diseases: A mendelian randomization study. Clin Nutr ESPEN. 2024;63:447. doi:10.1016/j.clnesp.2024.06.018
- Tian S, Guo T, Qian F, Qiu Z, Lu Q, et al. Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications among Individuals with Type 2 Diabetes. J Clin Endocrinol Metab. 2024. doi:10.1210/clinem/dgae482
- Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. doi:10.1093/eurjpc/zwae184
- Braun TS, Drobner T, Kipp K, Kiehntopf M, Schlattmann P, et al. Validation of Nutritional Approaches to Modulate Cardiovascular and Diabetic Risk Factors in Patients with Hypertriglyceridemia or Prediabetes-The MoKaRi II Randomized Controlled Study. Nutrients. 2024;16. doi:10.3390/nu16091261
- O'Keefe EL, O'Keefe JH, Tintle NL, Westra J, Albuisson L, et al. Circulating Docosahexaenoic Acid and Risk of All-Cause and Cause-Specific Mortality. Mayo Clin Proc. 2024;99:534. doi:10.1016/j.mayocp.2023.11.026
- Zeinalabedini M, Ladaninezhad M, Mobarakeh KA, Hoshiar-Rad A, Shekari S, et al. Association of dietary fats with ischemic heart disease (IHD): a case-control study. J Health Popul Nutr. 2024;43:19. doi:10.1186/s41043-023-00489-w
- Rennemo J, Berge K, Yousaf MN, Eriksen TB, Welde E, et al. An Atypical Course of Cardiomyopathy Syndrome (CMS) in Farmed Atlantic Salmon () Fed a Clinical Nutrition Diet. Microorganisms. 2023;12. doi:10.3390/microorganisms12010026
